{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:27Z","timestamp":1786119447148,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:p>\n                    Chemotherapy has markedly improved the prognosis of childhood leukemia, yet chemotherapy-induced liver injury (CILI) remains a significant complication. This study aimed to evaluate the incidence and risk factors of CILI in a single-center retrospective cohort of 240 children with leukemia diagnosed between January 2023 and December 2024 who received chemotherapy. Liver injury was graded using CTCAE v5.0, and clinical and treatment-related variables were analyzed by\n                    <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                    \u00b2 test and logistic regression. Overall, 62 patients (25.8%) developed CILI, most commonly characterized by hepatocellular injury (51.6%). The median time to onset was 12 days, with recovery at 15 days. Univariate analysis suggested associations with baseline liver dysfunction and infectious events, and multivariable regression confirmed both baseline hepatic abnormalities (OR\u2005=\u20052.73, 95% CI: 1.25\u20135.97,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.012) and infections (OR\u2005=\u20052.18, 95% CI: 1.09\u20134.35,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.028) as independent risk factors. CILI is common during chemotherapy for childhood leukemia, with baseline liver impairment and infection significantly increasing risk. Strengthening pretreatment evaluation, dynamic monitoring, and infection control, along with incorporating pharmacogenomics into risk prediction models, may improve individualized management and enhance treatment safety.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046126","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:01:13Z","timestamp":1767711673000},"page":"e46126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Study on the occurrence characteristics and influencing factors of chemotherapy-related liver function injury in children with leukemia"],"prefix":"10.1097","volume":"105","author":[{"given":"Rongfang","family":"Ding","sequence":"first","affiliation":[{"name":"Children\u2019s Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Children\u2019s Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Yi","sequence":"additional","affiliation":[{"name":"Children\u2019s Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Children\u2019s Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8254-6166","authenticated-orcid":false,"given":"Qiujun","family":"Liu","sequence":"additional","affiliation":[{"name":"Children\u2019s Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children.","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20260218","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014.","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration.","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"e27747","DOI":"10.1002\/pbc.27747","article-title":"Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.","volume":"66","author":"Miller","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/liv.12836","article-title":"Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.","volume":"35","author":"Aithal","year":"2015","journal-title":"Liver Int"},{"key":"R6-20260218","first-page":"47","article-title":"Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.","volume":"85","author":"Uderzo","year":"2000","journal-title":"Haematologica"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"10.1002\/pbc.26891","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20260218","first-page":"CD008205","article-title":"Hepatic late adverse effects after antineoplastic treatment for childhood cancer.","volume":"4","author":"Mulder","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20260218","first-page":"CD008205","article-title":"Hepatic late adverse effects after antineoplastic treatment for childhood cancer.","volume":"2011","author":"Mulder","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20260218","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.anpedi.2019.01.003","article-title":"Lesi\u00f3n hep\u00e1tica inducida por quimioterapia en ni\u00f1os [Chemotherapy-induced liver injury in children].","volume":"91","author":"Urrutia-Maldonado","year":"2019","journal-title":"An Pediatr (Engl Ed)"},{"key":"R11-20260218","first-page":"5914593","article-title":"Drug-induced liver injury during consolidation therapy in childhood acute lymphoblastic leukemia as assessed for causality using the updated RUCAM.","volume":"2022","author":"Qin","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R13-20260218","doi-asserted-by":"crossref","first-page":"e000858","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/08880010802016706","article-title":"Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy.","volume":"25","author":"Shiozawa","year":"2008","journal-title":"Pediatr Hematol Oncol"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"e27634","DOI":"10.1002\/pbc.27634","article-title":"Nonneutropenic fever in children with cancer: a scoping review of management and outcome.","volume":"66","author":"Allaway","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.3390\/jcm10194419","article-title":"L-asparaginase toxicity in the treatment of children and adolescents with acute lymphoblastic leukemia.","volume":"10","author":"Schmidt","year":"2021","journal-title":"J Clin Med"},{"key":"R17-20260218","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia.","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-20260218","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R19-20260218","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia.","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"R20-20260218","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jdv.19897","article-title":"European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes).","volume":"38","author":"Kandolf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R21-20260218","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2012.07.009","article-title":"Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: prevalence and risk factors.","volume":"49","author":"Mulder","year":"2013","journal-title":"Eur J Cancer"},{"key":"R22-20260218","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3390\/ijms26052006","article-title":"Drug-induced liver injury-pharmacological spectrum among children.","volume":"26","author":"Maris","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R23-20260218","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/pgs-2020-0080","article-title":"Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamide regimen in breast cancer patients.","volume":"22","author":"Huang","year":"2021","journal-title":"Pharmacogenomics"},{"key":"R24-20260218","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/00498254.2013.858849","article-title":"Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat.","volume":"44","author":"Xu","year":"2014","journal-title":"Xenobiotica"},{"key":"R25-20260218","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer.","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:29Z","timestamp":1786041209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046126","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-09-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}